A share price of Kymera Therapeutics Inc [KYMR] is currently trading at $41.2, down -1.32%. An important factor to consider is whether the stock is rising or falling in short-term value. The KYMR shares have lost -6.58% over the last week, with a monthly amount drifted -5.83%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
On June 03, 2025, upgrade upgraded it’s rating to Overweight but maintained its price target of $79 on the stock. B. Riley Securities upgraded its rating to a Buy but stick to its price target of $60 on June 03, 2025. BofA Securities upgraded its rating to a Buy but $51 remained the price target by the analyst firm on June 02, 2025. In a note dated March 13, 2025, Citigroup initiated a Buy rating and provided a target price of $52 on this stock.
Kymera Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $19.44 and $53.27. Currently, Wall Street analysts expect the stock to reach $59 within the next 12 months. Kymera Therapeutics Inc [NASDAQ: KYMR] shares were valued at $41.2 at the most recent close of the market. An investor can expect a potential return of 43.2% based on the average KYMR price forecast.
Analyzing the KYMR fundamentals
Trailing Twelve Months sales for Kymera Therapeutics Inc [NASDAQ:KYMR] were 44.71M which represents -55.26% decline. Gross Profit Margin for this corporation currently stands at 0.95% with Operating Profit Margin at -6.98%, Pretax Profit Margin comes in at -6.16%, and Net Profit Margin reading is -6.16%. To continue investigating profitability, this company’s Return on Assets is posted at -0.24, Equity is -0.32 and Total Capital is -0.3. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.09.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 40.67 points at the first support level, and at 40.14 for the second support level. However, for the 1st resistance point, the stock is sitting at 42.04, and for the 2nd resistance point, it is at 42.88.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Kymera Therapeutics Inc [NASDAQ:KYMR] is 8.32. On the other hand, the Quick Ratio is 8.32, and the Cash Ratio is 3.84. Considering the valuation of this stock, the price to sales ratio is 65.88, the price to book ratio is 2.99.
Transactions by insiders
Recent insider trading involved BVF PARTNERS L P/IL, Director, that happened on Jun 30 ’25 when 0.32 million shares were purchased. Director, BAKER BROS. ADVISORS LP completed a deal on Jun 30 ’25 to buy 0.66 million shares. Meanwhile, Director Ridloff Elena sold 4500.0 shares on Jun 11 ’25.
